|
Jul 1
|
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading
|
|
Jun 26
|
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
|
|
Jun 26
|
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
|
|
Jun 25
|
European Penny Stocks To Watch In June 2025
|
|
Jun 24
|
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
|
|
May 12
|
Cellectis Reports Financial Results for the First Quarter 2025
|
|
May 6
|
Cellectis to Report First Quarter Financial Results on May 12, 2025
|
|
Apr 25
|
3 European Penny Stocks With At Least €100M Market Cap
|
|
Apr 21
|
Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...
|
|
Mar 13
|
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
|
|
Feb 24
|
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
|
|
Dec 29
|
Analysts Predict 400% Upside Potential for This Penny Stock
|
|
Aug 26
|
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
|
|
Aug 7
|
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
|
|
Aug 6
|
Cellectis Provides Financial Results for the Second Quarter 2024
|
|
Jul 25
|
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
|
|
Jun 12
|
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
|
|
May 7
|
AstraZeneca concludes equity investment in Cellectis
|
|
May 6
|
AstraZeneca ups stake in Cellectis in latest cell therapy bet
|
|
May 6
|
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
|